4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition (Time Zone - EST)

28th -1st July 2021
CONFERENCE SPEAKERS
Speakers
Juan Perez Villar
Juan Perez Villar
CEO,
LeadArtis



John Burke
John Burke
CEO, Co-Founder, President,
Applied BioMath



Jenna Frame
Jenna Frame
Senior Scientist, Scientific Communications,
Biocytogen



Keith Wharton
Keith Wharton
VP, Medical Director,
Ultivue, USA


Keith is a board-certified anatomic pathologist with diverse achievements in research and drug/diagnostic development.  Leading Ultivue’s Assay Services Laboratory, he brings expertise in investigative pathology, multiplex microscopy and imaging, and digital pathology to our customers striving to realize the promise of personalized medicine.  Most recently he was Senior Medical Director of Leica Biosystems, and prior to that he led and supported R&D, toxicology, biomarker, and clinical study teams in multiple therapeutic areas at Novartis and Biogen.

He earned a BS in Chemical Engineering from the University of Arizona, and MD and PhD in Molecular Biology from UCLA, where he discovered the molecular basis of DNA recognition by bHLH-PAS transcription factors.  Following residency and postdoc at Stanford, his lab at UT Southwestern characterized the Naked cuticle (Nkd) gene family as feedback regulators of Wnt-beta catenin signaling.


Victor Levitsky
Victor Levitsky
Chief Scientific Officer,
Targovax



Tomasz Burzykowski
Tomasz Burzykowski
Vice President, Research,
IDDI



Steven Lynum
Steven Lynum
Executive Director Global Business Development,
PHC Corporation



Héctor Pérez Montoyo
Héctor Pérez Montoyo
Director, Biological Research,
Ability Pharma



Laura Codarri Deak
Laura Codarri Deak
Principal Scientist, Team Leader,
Cancer Immunotherapy, Roche



Mark Exley
Mark Exley
Chief Scientific Officer,
ImVax



Helena Kiefel
Helena Kiefel
Program Leader, Immuno-Oncology,
Second Genome



Lindy Durrant
Lindy Durrant
Professor, Cancer Immunotherapy,
University of Nottingham, UK


Lindy is Professor of Cancer Immunotherapy at the University of Nottingham and CSO of Scancell Ltd. She has developed a panel of mabs recognised tumour associated glycans and has pioneered an new antibody engineering technology which enhances the avidity of mabs,  termed Avidimabs. This has been applied to the anti-glycan mabs resulting in direct killing mabs. She has developed two vaccine platforms ImmunoBodyTM and ModitopeTM which induce potent killer CD8 T cells and and cytotoxic CD4 T cells to post-translational modifications respectively. The first ImmunoBodyTM, SCIB1, has completed a phase I/II clinical trial in which 14/16 patients with melanoma have been disease free for five years. The first product from the ModitopeTM platform will enter the clinic next year. Lindy has over 150 peer reviewed publications and is also the inventor on 66 patents. She was award of the Waldenstrom prize for cancer Immunotherapy in 2018.


De Yang
De Yang
Staff Scientist,
NIH, National Cancer Institute, Center for Cancer Research



Sari Pesonen
Sari Pesonen
Co-Founder, Head, R&D,
Valo Therapeutics



Stephen Schoenberger
Stephen Schoenberger
Professor, Center for Cancer Immunotherapy,
La Jolla University



Dirk Brockstedt
Dirk Brockstedt
Chief Scientific Officer,
RAPT Therapeutics



Stefan Glueck
Stefan Glueck
Senior Vice President, Global Medical Affairs,
Celgene


Stefan Glück, MD, PhD, is V.P. Global Medical Affairs, at Celgene Corporation since October 2014, and a hematologist and medical oncologist with focus on breast cancer. He has overseen oncology activities worldwide, as well as the Immuno-Oncology Program in solid tumors and hematology. Recently, his job requirements have shifted to include Early Assets. He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 - December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has authored or co-authored over 270 articles


William Williams
William Williams
President, CEO,
Briacell Therapeutics Corporation


Dr. Williams is the President and CEO of BriaCell Corporation, where he has shepherded Bria-IMT™ into the clinic, established positive proof-of-concept, forged a collaboration with Incyte for novel combinations and coordinated the development of an off-the-shelf personalized approach to cancer immunotherapy. While at Incyte Corporation as Head of Exploratory Development, he brought numerous molecules into the clinic and established proof of concept in several disease areas. At GlaxoSmithKline he worked to bring several molecules into the clinic, ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug development. At the University of Pennsylvania, he developed novel methods of bioactive peptide design, ran a major research program in receptor biology, and was able to bring novel therapies into the clinic.  He has been involved in several successful new drug applications, including drugs for lymphoma, ovarian cancer, osteoporosis, nausea and vomiting, myelofibrosis and polycythemia vera.


Paul Lammers
Paul Lammers
President & CEO,
Triumvira Immunologics



Roxana Schillaci
Roxana Schillaci
Head, R&D,
Immune Bio



Pamela Reilly Contag
Pamela Reilly Contag
CEO,
BioEclipse Therapeutics



Shahram Salek-Ardakani
Shahram Salek-Ardakani
Senior Director, Cancer Immunology,
Pfizer


Dr. Shahram Salek-Ardakani is a Senior Director in Cancer Immunology Discovery Unit at Pfizer. His Research focuses predominantly on mechanisms of T cell memory, dendritic cell activation, and immune regulation by members of the TNF/TNFR superfamily. His group uses a variety of molecular, cellular, and biochemical techniques, as well as live cell imaging approaches to further understand biological pathways related to cancer immunotherapy. His current roles include liaisons across Early Discovery Research, Clinical and Translational Oncology and Business Development. Dr. Salek-Ardakani completed his PhD at the Patterson Institute for Cancer Research, University of Manchester, U.K, and his postdoctoral training at the La Jolla Institute for Allergy and Immunology in San Diego, CA. Dr. Salek-Ardakani has served on a number of grant review study sections and special emphasis panels for the National Institute of Health and has served on the advisory boards of professional conferences and a faculty of many seminars.


Pamela Esposito
Pamela Esposito
Chief Business Officer,
Replimmune



Paul Parren
Paul Parren
EVP and Head of R&D,
Lava Therapeutics



Eric Halioua
Eric Halioua
President & CEO,
PDC*line Pharma



Yaron Pereg
Yaron Pereg
CEO,
KAHR Bio



Laura Codarri
Laura Codarri
Principal Scientist, Team Leader, Cancer Immunotherapy,
Roche



Marc Yeste-Velasco
Marc Yeste-Velasco
Director, Translational Research & Scientific Licensing,
Ability Pharma



Mahendra Deonarain
Mahendra Deonarain
Chief Executive and Science Officer,
Antikor Biopharma



Bonnie Hammer
Bonnie Hammer
Vice President, Research & Development,
Invenra